Related Experiment Video

Updated: Mar 31, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

Potential lipid-lowering effects of Coffea arabica pulp extract product in hyperlipidemia-obese subjects: a

Supawan Buranapin¹, Atcharaporn Ontawong², Chutima S Vaddhanaphuti³

¹Section of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Frontiers in Nutrition

|March 30, 2026

Abstract

Background:

Coffea arabica pulp aqueous extract (CPE) exhibits anti-hyperlipidemia, anti-hyperglycemia, and anti-inflammatory effects in vitro and in vivo. This randomized, double-blind, controlled study evaluated the lipid-lowering effects of the CPE product in hyperlipemia-obese participants.

Methods:

Seventy-nine obese men and women [BMI ≥ 25 kg/m² and low-density lipoprotein cholesterol (LDL-C) ≥ 130 mg/dL] were randomly allocated to the CPE product and control groups. The CPE product or placebo was consumed twice daily for 24 weeks. The lipid profiles, BW, BMI, fat mass, and diabetic diagnosis parameters were assessed alongside adverse events measurements.

Results:

Within-group analysis showed a significant reduction of LDL-C, triglyceride (TG), and total cholesterol (TC) levels by 14.9, 18.9, and 8.0%, respectively, while increasing high-density lipoprotein cholesterol (HDL-C) levels by 6.0% in the CPE product group compared to baseline after 24 weeks of intervention. In the placebo group, LDL-C and HDL-C levels decreased significantly by 7.7 and 5.3%, respectively, at week 24, but TC and TG levels did not change significantly. After adjustment for screening lipid values, the CPE group showed greater reductions in total cholesterol, triglycerides, and LDL-C than the placebo group (-6.3% vs. -2.4%, p = 0.048; -12.5% vs. +1.17%, p = 0.078; and -13.7% vs. -7.1%, p = 0.01, respectively). HDL-C increased in the CPE group but decreased in the placebo group after adjustment (+7.1% vs. -5.0%, p < 0.0001). The adverse events were not different between the experimental groups.

Conclusion:

This study suggests that the CPE product could be a nutraceutical product option for lowering lipids in hyperlipidemic patients. However, this study has limitations, including the short treatment period, the small number of enrolled participants, and its exploratory nature.

Clinical Trail Registration:

This study was registered at the Thai Clinical Trial Registry with the identification number 20241117005. https://www.thaiclinicaltrials.org/.

Keywords:

CPE product coffee pulp aqueous extract hyperlipidemia lipid profiles obese

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Articles linked to this work by shared authors, journal, and citation graph.

Lipid-lowering and hepatoprotective effects of Ocimum sanctum L. (Thai holy basil) flower against MASLD and liver inflammation in rats.

Food research international (Ottawa, Ont.)·2026

Modulatory Effects of Piper sarmentosum Roxb. Aqueous Extract on Gut Microbiota and Obesity in a High-Fat Diet Rat Model.

Nutrients·2026

Skipjack tuna bone-derived biocalcium ameliorates osteoblast and osteoclast differentiation through microRNA21 regulation.

iScience·2026

Coffea arabica pulp aqueous extract exhibits the anti-colitogenic effect in mice: preventive efficacy and possible mechanisms of action.

Biological research·2026

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.

Diabetes, obesity & metabolism·2026

Bioactive Effects of Plectranthus amboinicus Extract Using Microwave Techniques and Its Value Addition in Cosmeceutical Products.

F1000Research·2026

See all related articles